High-dose IL-2 demonstrates potential, inducing objective responses in up to 15% of patients with metastatic melanoma and RCC, with some patients achieving durable complete responses [7, 10, 91, 155, 156]. This evidence concerns the gene IL2 and metastatic melanoma.